debrisoquin and tolterodine tartrate

debrisoquin has been researched along with tolterodine tartrate in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (66.67)	18.2507
2000's	1 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alván, G; Bertilsson, L; Brynne, N; Dalén, P; Gabrielsson, J	1
Bertilsson, L; Böttiger, Y; Brynne, N; Hallén, B	1
Dorne, JL; Renwick, AG; Slob, W; Walton, K	1

Trials

2 trial(s) available for debrisoquin and tolterodine tartrate

Article	Year
Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clinical pharmacology and therapeutics, 1998, Volume: 63, Issue:5 Topics: Administration, Oral; Adult; Area Under Curve; Benzhydryl Compounds; Cresols; Cytochrome P-450 CYP2D6; Debrisoquin; Half-Life; Heart Rate; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Muscarinic Antagonists; Phenotype; Phenylpropanolamine; Polymorphism, Genetic; Salivation; Tolterodine Tartrate	1998
Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. British journal of clinical pharmacology, 1999, Volume: 47, Issue:2 Topics: Adult; Anti-Ulcer Agents; Antihypertensive Agents; Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Cresols; Cross-Over Studies; Cytochromes; Debrisoquin; Drug Interactions; Humans; Male; Muscarinic Antagonists; Omeprazole; Phenylpropanolamine; Polymorphism, Genetic; Tolterodine Tartrate; Urinary Bladder Diseases	1999

Article

Year

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.

Clinical pharmacology and therapeutics, 1998, Volume: 63, Issue:5

Topics: Administration, Oral; Adult; Area Under Curve; Benzhydryl Compounds; Cresols; Cytochrome P-450 CYP2D6; Debrisoquin; Half-Life; Heart Rate; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Muscarinic Antagonists; Phenotype; Phenylpropanolamine; Polymorphism, Genetic; Salivation; Tolterodine Tartrate

1998

Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.

British journal of clinical pharmacology, 1999, Volume: 47, Issue:2

Topics: Adult; Anti-Ulcer Agents; Antihypertensive Agents; Benzhydryl Compounds; Caffeine; Central Nervous System Stimulants; Cresols; Cross-Over Studies; Cytochromes; Debrisoquin; Drug Interactions; Humans; Male; Muscarinic Antagonists; Omeprazole; Phenylpropanolamine; Polymorphism, Genetic; Tolterodine Tartrate; Urinary Bladder Diseases

1999

Other Studies

1 other study(ies) available for debrisoquin and tolterodine tartrate

Article	Year
Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2002, Volume: 40, Issue:11 Topics: Adult; Aged; Aging; Benzhydryl Compounds; Cresols; Cyclohexanols; Cytochrome P-450 CYP2D6; Debrisoquin; Desipramine; Encainide; Ethnicity; Genetic Variation; Humans; Hydroxylation; Infant; Infant, Newborn; Kidney Diseases; Kinetics; Liver Diseases; Metabolic Clearance Rate; Metoprolol; Phenylpropanolamine; Polymorphism, Genetic; Propafenone; Substrate Specificity; Tolterodine Tartrate; Venlafaxine Hydrochloride	2002

Article

Year

Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2002, Volume: 40, Issue:11

Topics: Adult; Aged; Aging; Benzhydryl Compounds; Cresols; Cyclohexanols; Cytochrome P-450 CYP2D6; Debrisoquin; Desipramine; Encainide; Ethnicity; Genetic Variation; Humans; Hydroxylation; Infant; Infant, Newborn; Kidney Diseases; Kinetics; Liver Diseases; Metabolic Clearance Rate; Metoprolol; Phenylpropanolamine; Polymorphism, Genetic; Propafenone; Substrate Specificity; Tolterodine Tartrate; Venlafaxine Hydrochloride

2002